1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Insulin Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030

Insulin Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021
  • 175 pages
  • ID: 6151550
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the insulin drugs market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, and NovoRapid/Novolog.

The global insulin drugs market is expected to grow from $25.88 in billion 2020 to $27.2 billion in 2021 at a compound annual growth rate (CAGR) of 5.1%.The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $32.05 billion in 2025 at a CAGR of 4%.

The insulin drugs market consists of manufacturers’ sales of insulin drugs and types of Insulin by entities (organizations, sole traders and partnerships) which are used to treat diabetes.Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus.

There are several types, preparations, and dosage amount of insulin.Insulin is a hormone that is produced naturally in our bodies.

Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. The market covered in this report does not include non-insulin drugs and other antidiabetic drugs or medicine.

The insulin drugs market covered in this report is segmented by product type into basal or long acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, biosimilar insulins. It is also segmented by application into type II diabetes, type I diabetes, gestational diabetes, prediabetes.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

High costs and long payback periods for investment in new diabetes drugs negatively impacted the market during the forecast period.The costs for drug approval processes that include multiple phases of clinical trials and screening processes with regulatory bodies such as the US FDA are very high.

According to a study published in the journal JAMA, the cost of bringing a new drug from its conception to shelves was about $2.8 billion in 2020. These high costs and uncertainty regarding return on investments for drug development limited the investments by pharmaceutical companies in the development of new diabetic drugs, thus limiting the growth of the market during the historic period.

In September 2019, Vertex Pharmaceuticals, an America based Biopharmaceutical company acquired Semma Therapeutics for $950 million.Through this acquisition Vertex has turned to potentially curative technologies like CRISPR genome editing and synthetic messenger RNA for its next generation of products.

Semma Therapeutics, a USA based company that develops transformative therapies for Type 1 diabetes patients.

Changing lifestyles are leading to a higher prevalence of diabetes.This is expected to drive the demand for diabetes drugs during the forecast period.

Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of diabetes.According to a study conducted in 2018, there was a high prevalence of diabetes in people with sedentary lifestyles.

Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes.According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030.

These factors are expected to increase the patient pool of diabetes, thereby likely to drive the diabetes therapies market during the forecast period.

There is an increased trend of mergers and acquisitions for the new formulations in Insulin market and the companies are investing in development of new medicines in Insulin drugs market.For example, researchers at Lund University Diabetes Centre in Sweden, worked on CRISPR, a genome modification tool.

This resulted in turning off of one of the genes which was responsible for causing diabetes.This effectively decreased beta cell death and increased insulin production in the pancreas.

Insulin maker, Novo Nordisk has developed a diabetes pill and it is expected to be launched in 2020.This pill belongs to a blockbuster class of drugs, glucagon like peptide-1 (GLP-1s) that stimulate insulin production.

The new drug is expected to generate about $5 billion in annual sales.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Oral Proteins & Peptides Market Research Report by Drug Type, by Application, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 195 pages

Oral Proteins & Peptides Market Research Report by Drug Type (Calcitonin, Insulin, and Linaclotide), by Application (Bone Diseases, Diabetes, and Gastric & Digestive Disorders), by State (California, Florida, ...

  • United States
  • Musculoskeletal Disorder
  • Digestive System Disorder
  • Industry analysis

Insulin Markets in China $ 4000 June 2021

Insulin Companies in China $ 1800 June 2021


ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on